33 results about "Poorly differentiated" patented technology

Methods of diagnosing whether an epithelial tissue is an abnormal tissue by determining an expression pattern for PML in the epithelial tissue; determining an expression pattern for nuclear bodies in the epithelial tissue; determining SUMO-1 colocalization and comparing the expression pattern for PML and the expression pattern for nuclear bodies with a control are disclosed. Also disclosed are methods for diagnosing whether a subject has mild dysplasia, moderate dysplasia, Type A severe dysplasia, Type B severe dysplasia, cervical squamous cell carcinoma, or poorly-differentiated cervical squamous cell carcinoma, by determining an expression pattern for PML, an expression pattern for nuclear bodies, and SUMO-1 colocalization and determining whether the sample is consistent with expression patterns expected for mild dysplasia, moderate dysplasia, Type A severe dysplasia, Type B severe dysplasia, cervical squamous cell carcinoma, or poorly-differentiated cervical squamous cell carcinoma.

The invention relates to a breast cancer recurrent risk assessment 21 gene detection primer and application thereof. The breast cancer recurrent risk assessment 21 gene detection primer comprises a nucleotide sequence as shown in an SEQ ID NO.: 1 to 42, and belongs to the technical field of molecular detection. The detection primer provided by the invention utilizes the advantage of fluorescent quantitation, and adopts fluorescent quantitation polymerase chain reaction to carry out amplification detection on 21 genes for breast cancer recurrent risk assessment, so that whether clinical measurements such as adjuvant chemotherapy are needed or not is considered. A kit provides a PCR (Polymerase Chain Reaction) amplification primer sequence of the 21 genes for breast cancer recurrent risk assessment, and the primer is applicable to detecting ER positive patients, HER2 negative patients, axillary node negative patients, moderately and poorly differentiated patients with the tumor size being 0.6 to 1.0cm and adverse prognostic factors, or patients with the tumor size is larger than 1cm, has the advantages of high sensitivity and specificity, stability, promptness, convenience in operation and the like, can well meet the clinical application of breast cancer recurrent risk assessment, and can be beneficial for reducing invalid medication administration, improving medication administration accuracy, and reducing financial burdens of the patients.

Phage display was used to screen peptide libraries that distinguish between well-differentiated (HCT116) and poorly-differentiated colon carcinoma cells (HT29). The screening protocol used selection and subtraction on intact, viable cells, resulting in phage libraries exhibiting high binding selectivity for the poorly-differentiated HT29 cells. A nine amino acid, disulfide-constrained peptide (RPM) was identified that selectively bound and was internalized into colon cancer cells. The peptide may be used to detect colon cancer cells and also may be used to selectively deliver therapeutic agents to the cells.

The invention discloses a 5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound, a preparing method, an application and a drug composite containing the compound thereof. More specifically, the invention discloses a 5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound as shown in the formula I, a preparing method and an application thereof. By the growth inhibition test of various tumour cell lines (human breast cancer cells MDA-MB-435, p53-deleted poorly differentiated colorectal adenocarcinoma cells Hct116p53- / -, p53-enriched poorly differentiated colorectal adenocarcinoma cells Hct116p53+ / +, human breast cancer cells Mcf-7, NIH189, human breast cancer cells SkBr-3, prostatic cancer cells LnCap, LnHer, human colorectal cancer cells HT29 and human ovarian cancer cellsHEY), the compound has favourable inhibition activity for the above tumour cells and can treat diseases caused by tumour cell malignant proliferation. The invention also discloses a drug composite containing the compound.

The invention discloses a cell strain from human prostate cancer. The cell is named as human prostate cancer cell HPCC / HL-002, and the preservation number is CCTCCNO:C2013102. The cell strain is prepared from an exairesis cancer tissue sample of a prostate cancer patient with T3b poorly differentiated adenocarcinoma according to clinical stages, has typical tumor cellular biology characteristics, can be continuously passed for a long time in vitro, and is kept stable in character. In addition, the invention further discloses a preparation method of the cell strain. The human prostate cancer cell disclosed by the invention has the biology characters of clinical essential prostate, and can be applied to molecular mechanism researches on pathogenesis, invasion and metastasis of prostate, pharmacodynamics study and detection on anti-cancer medicines selected in vitro.

Phage display was used to screen peptide libraries that distinguish between well-differentiated (HCT116) and poorly-differentiated colon carcinoma cells (HT29). The screening protocol used selection and subtraction on intact, viable cells, resulting in phage libraries exhibiting high binding selectivity for the poorly-differentiated HT29 cells. A nine amino acid, disulfide-constrained peptide (RPM) was identified that selectively bound and was internalized into colon cancer cells. The peptide may be used to detect colon cancer cells and also may be used to selectively deliver therapeutic agents to the cells.

The invention relates to the field of cell culture, and discloses a method for reversing failure of anti-tumor infiltrating lymphocytes and an application of the method, wherein the method, by virtue of a means of adding a cell factor composition, can achieve the purposes of better preserving tumor infiltrating lymphocytes and promoting the poorly differentiated phenotype of T cells of the tumor infiltrating lymphocytes. Compared with a conventional anti-tumor T cell in-vitro culture method, the method disclosed by the invention can creatively delay a process of in-vitro tumor infiltrating lymphocyte failure, and the anti-tumor T lymphocytes, at a low concentration, can show an efficient tumor suppression activity in an in-vitro pre-clinical experimental model. The method disclosed by the invention is simple and easy to implement, low in cost, better in effect and broad in clinical application prospect.

The invention relates to Papanicolaou staining fluid and a using method thereof. The Papanicolaou staining fluid consists of fluid A, fluid B and 95 percent ethanol, wherein the fluid A is improved hematoxylin staining fluid; the fluid B is prepared from a phosphotungstic acid, eostm and light green. A method for preparing the improved hematoxylin staining fluid comprises the following steps of dissolving hematoxylin into the 95 percent ethanol, dissolving potassium alum into 100 DEG C boiling water, mixing two mixed solutions, adding an oxidant, stirring for at least 50 minutes, adding a glacial acetic acid, and stirring for at least 50 minutes. A method for preparing the fluid B comprises the following steps of mixing 95 to 97 mass percent of 0.2 to 0.6 percent phosphotungstic acid solution, 1.5 to 2.5 mass percent of eostm solution and 1.5 to 2.5 mass percent of light green solution. When the Papanicolaou staining fluid is used, a smear is fixed in the 95 percent ethanol, and is flushed in a specific environment by adding a corresponding amount of fluid A and a corresponding amount of fluid B. The Papanicolaou staining fluid has the advantages of low cost, bright color, clear contrast, coloring stability, is simple to prepare and convenient to operate, is easily popularized and used in various medical units and the like, and is applied to the display and diagnosis of the estrogen level of a vaginal smear and the poorly-differentiated small-angle cell carcinoma of a cervical smear and a sputum smear.

The invention provides a hairpin polyamide compound (I) modified by chiral (S)-beta-hydroxyl-gamma-amino acid, and an application for the same in preparation of anti-tumour medicines. The compound is of a hairpin structure, and contains (S)-beta-hydroxyl-gamma-amino acid residue (S gamma beta-OH) with a specific identification function for the basic group T of DNA (deoxyribonucleic acid); additionally, the compound further contains common N-methylpyrrole residue (Py), N-methylimidazole residue (Im), gamma-amino acid residue and beta-alanine residue. Experiments indicate that the hairpin polyamide compound provided by the invention has a strong killing effect on tumour cells BEL7402 (liver cancer) and MKN45 (poorly-differentiated gastric cancer), and the compound III is the strongest in expression, and has essential significance on research and development for anti-tumour gene targeted medicines down-regulated by chirally-modified polyamide mediate c-kit gene.

Methods of treating a disease or disorder characterized by cells with increased or aberrant expression of cytokeratin-8 (CK8) are disclosed. The methods typically include administering to a subject in need thereof a pharmaceutical composition including an effective amount of a CK8 inhibitor. Exemplary diseases include thyroid cancers, particularly thyroid cancers characterized by poorly differentiated or undifferentiated cells. In the most preferred embodiments the cancer is an anaplastic thyroid cancer or a poorly differentiated papillary thyroid cancer. Disclosed inhibitors include, functional nucleic acids, inhibitory anti-CK8 antibodies, inhibitory peptides, and small molecules.

The invention discloses a method for constructing a liver cancer patient-derived chick chorioallantoic membrane M-PDX model. The method comprises the following steps: clinical sample transport, cryopreservation, resuscitation and transplantation. A human hepatic transplantable tumor and an angiogenesis model thereof are established on the chick chorioallantoic membrane (CAM) by using human hepatoma cells with poor differentiation and high metastasis to provide a simple and practical way for the study of hepatic transplantable tumor and angiogenesis thereof. Compared with conventional models, the model has the unique advantages of short experimental period, low cultivation cost, and convenience in operation.

The invention discloses an application of borneol in promoting a poorly differentiated nasopharyngeal cell to intake adriamycin through chloride channel mediation. With the human poorly differentiated nasopharyngeal cell (CNE-2Z) as a research object, the conclusions are explored from the angle of the chloride channel as follows: (1) the chloride channel can be an action target point of the borneol in promotion of adriamycin transportation across a CNE-2Z cytomembrane; (2) the borneol can activate a CNE-2Z cell chloride current, and the current has volume sensitivity; (3) the ClC-3 chloride channel plays an important role in promotion of adriamycin transportation across the CNE-2Z cytomembrane by the borneol; and (4) the anti-tumor effect of the adriamycin can be obviously improved by combination of the borneol and the adriamycin. The mechanism of the borneol in promotion of drug uptake through the cytomembrane is expected to be diluted from the angle of the chloride channel by discussing the relationship between the chloride channel and the drugs taken by the cell in different states; and a new theoretical basis is provided for the borneol in clinical application.

Provided are methods and kits for staining cervical cell sample by contacting the cervical cell sample with a Ficus elastics plant extract, staining the cervical cell sample with New Fuchsin, and staining the cervical cell sample with Light Green or Fast Green. Also provided are method of diagnosing a pre-malignant or a malignant cervical tumor in a subject, by staining the cervical cell sample and identifying at least one cervical cell having a red cytoplasm above a pre-determined threshold, wherein presence of the at least one cervical cell having the red cytoplasm above the pre-determined threshold is indicative of a non- or less-differentiated cell as compared to a normal cervical cell, thereby diagnosing the pre-malignant or a malignant cervical tumor in the subject.

The invention discloses a poorly differentiated thyroid cancer cell line PDTC-1 and applications thereof. The cell line is a poorly differentiated thyroid cancer cell line, and the accession number thereof is CGMCC No. 4939. The present invention establishes a poorly differentiated thyroid carcinoma cell line, successfully establishes a nude-mouse transplanted tumor model by using the cell line, provides a screenable cell line for the study of thyroid cancer cytology, and the cell line can be used for establishing important models for screening thyroid cancer-sensitive chemotherapy drugs. On the basis of the present invention, differences of differentiated, poorly differentiated and undifferentiated thyroid cancers can be studied from the genetic level and the protein level, having important meaning for elucidating the generating mechanism and finding therapeutic targets of the thyroid cancer. The cell line of the present invention provides a platform for the study of thyroid cancer evolution and biological characteristics of poorly differentiated cancers, and is conducive to the in-depth study of pathogenesis, metastasis and recurrence of thyroid cancer.

The present invention relates to a periplaneta americana extract effective part with cytotoxic activity, a preparation method and a medical purpose thereof. The periplaneta americana extract effective part of the present invention is refined from fresh or dry blattidae periplaneta americana body which is extracted by alcohol water, processed for macroporous resin column chromatography and is eluted by alcohol solvent. The periplaneta americana extract effective part obtained by the present invention has obvious cytotoxicity and internal anticancer efficacy towards oral epidermoid carcinoma (KB) cell, poorly differentiated gastric abenocarcinoma tumour (BGC-823) cell, human chronic myelogonium leukaemia cancer (K562) cell and human myelogonium leukaemia cancer cell (HL-60) and can be used for preparing for a drug and a health care product for remedying the tumours.

The invention belongs to the technical field of biomedical science, and particularly relates to targeted aptamer for human poorly differentiated gastric carcinoma cells and an application of the targeted aptamer. The sequence of the aptamer is 5'-ACACCAAAATCGTCCGTTTCGTTTTAGTCCGTCTCTTTAGGGTGT-3'. The aptamer disclosed by the invention has high specificity and high affinity, and can maintain favorable activity at 4 DEG C, 25 DEG C and 37 DEG C. The aptamer disclosed by the invention can be used as a molecular probe, and can perform specificity imaging and detection on the human poorly differentiated gastric carcinoma cells. The aptamer has favorable application prospects in the respects of prediction and diagnosis and treatment of poorly differentiated gastric carcinoma.

The invention discloses an SIX4 gene used as a molecular marker for assessing the malignant degree of oral squamous cell carcinoma. High-throughput sequencing and QPCR studies show that the content ofthe SIX4 gene in high differentiated oral squamous cell carcinoma is lower than that in low differentiated oral squamous cell carcinoma. According to the research results, the invention can also develop a kit for assessing the malignant degree of oral squamous cell carcinoma, which has a remarkable detection effect and can be widely popularized and applied in clinic.

The invention provides a hairpin polyamide compound (I) modified by chiral (S)-beta-hydroxyl-gamma-amino acid, and an application for the same in preparation of anti-tumour medicines. The compound is of a hairpin structure, and contains (S)-beta-hydroxyl-gamma-amino acid residue (S gamma beta-OH) with a specific identification function for the basic group T of DNA (deoxyribonucleic acid); additionally, the compound further contains common N-methylpyrrole residue (Py), N-methylimidazole residue (Im), gamma-amino acid residue and beta-alanine residue. Experiments indicate that the hairpin polyamide compound provided by the invention has a strong killing effect on tumour cells BEL7402 (liver cancer) and MKN45 (poorly-differentiated gastric cancer), and the compound III is the strongest in expression, and has essential significance on research and development for anti-tumour gene targeted medicines down-regulated by chirally-modified polyamide mediate c-kit gene.

The invention discloses a traditional Chinese medicine preparation for relieving gastric poorly differentiated adenocarcinoma. The traditional Chinese medicine preparation is prepared from astragalus membranaceus, rhizoma paridis chinensis, sun-dried ginseng, stir-fried largehead atractylodes rhizome, stir-fried white peony roots, rhodiola rosea, Chinese angelica, prepared rehmannia roots, rhizoma smilacis glabrae, Indian iphigenia bulb, barbed skullcap herb, rhizoma chuanxiong, rhizoma curcumae, wild buckwheat rhizome, suberect spatholobus stems, ganoderma lucidum, raw semen coicis, yangtao actinidia roots, wild chrysanthemum flowers, asiatic moonseed rhizome, flos sophorae and raw liquorice in a certain weight ratio. The traditional Chinese medicine preparation has the efficacy of clearing heat, removing toxicity, eliminating carbuncle, removing stasis, promoting the production of body fluid to relieve thirst, strengthening spleen and benefiting qi and can inhibit cancer cell spreading and strengthen physique of a patient, thereby controlling and relieving gastric poorly differentiated adenocarcinoma.

The invention discloses a tumor tissue in-vitro pathological staining kit. The tumor tissue in-vitro pathological staining kit is a kit developed aiming at leading Cetuximab to be used in new applications of tumor tissue in-vitro pathological staining, experiments verification finds that after the Cetuximab is subjected to fluorescent labeling and then used for tumor tissue in-vitro pathological staining, normal tissues and tumor tissues can be well distinguished, well-differentiated and poorly-differentiated tumor tissues can be distinguished to certain extent, and the kit can be used for tumor detection, thus realizing new use for approved drugs.

The invention relates to circRNA markers for diagnosing poorly differentiated adenocarcinoma of a stomach. The markers comprise five circRNAs, i.e., hsa_circ_0102434 shown in SEQ ID NO: 1, hsa_circ_0005505 shown in SEQ ID NO: 2, hsa_circ_0077837 shown in SEQ ID NO: 3, hsa_circ_0072309 shown in SEQ ID NO: 4 and hsa_circ_0070033 shown in SEQ ID NO: 5. The circRNA markers all have a certain diagnosisvalue to diagnosis on the poorly differentiated adenocarcinoma of the stomach, AUC, sensitivity and specificity of combined diagnosis all are superior to those of single circRNA assaying, in an AUC curve, the area is the maximum, the sensitivity and specificity can reach 90% or more, and thus, the circRNA markers are relatively-reliable specific biomarkers for diagnosing the poorly differentiatedadenocarcinoma of the stomach.

The invention discloses an adult nephroblastoma HANB cell strain with the collection number of CCTCC NO:C201133. A culturing method comprises the following steps of: culturing in-vitro ascites of a patient suffering from poorly-differentiated anaplastic nephroblastoma; passing; freezing for preserving; and recovering; the cell growing speed is high, the quantity is large, the quality is uniform, and a cell culturing method is simple; as proved by evaluation on the biological characteristics such as cell form, protein structure, chromosome, neoplastic rate and the like of the cell strain, the cell strain keeps the biological characteristics of a primary tumor; and due to the usage of the adult nephroblastoma HANB cell strain to the establishment of a nephroblastoma model, a research model is provided for the occurrence, transfer mechanism and clinical treatment of the nephroblastoma.

The invention discloses a monoclonal antibody resisting the ovarian cancer and application thereof. A hybridoma cell strain NM003-1 secreting the monoclonal antibody resisting the human ovarian cancer is preserved in China Center for Type Culture Collection on September 26, 2011 with the preservation number of CCTCC NO: C201174. The hybridoma cell strain NM003-1 secretes the monoclonal antibody NJ003-1 resisting the human ovarian cancer. Expression of a specific antigen of the monoclonal antibody NJ003-1 in ovarian cancer tissue is higher than that in ovarian benign disease tissue; the positive expression rate of the antigen in a poorly differentiated patient is higher than that in a well differentiated patient. The monoclonal antibody NJ003-1 can effectively inhibit clone formation of ovarian carcinoma cells SK-OV-3 in soft agar and can remarkably inhibit growth of human ovarian cancer transplantation tumors in a nude mouse. Obviously, the monoclonal antibody is expected to become medicine for treating the ovarian cancer or to be prepared into a diagnostic reagent for detecting the ovarian cancer.

The invention discloses a SIX4 gene regarded as a molecule marker for assessing oral squamous cell carcinoma metastatic potential. Through high-throughput sequencing and QPCR research, the fact that the content of the SIX4 gene in well differentiated oral squamous cell carcinoma is lower than that in poorly differentiated oral squamous cell carcinoma is informed. According to the research result,the invention further provides a kit used for assessing the oral squamous cell carcinoma metastatic potential, and the kit has an obvious detection effect, and can be clinically used.

The invention discloses a cell strain from human prostate cancer. The cell is named as human prostate cancer cell HPCC / HL-002, and the preservation number is CCTCCNO:C2013102. The cell strain is prepared from an exairesis cancer tissue sample of a prostate cancer patient with T3b poorly differentiated adenocarcinoma according to clinical stages, has typical tumor cellular biology characteristics, can be continuously passed for a long time in vitro, and is kept stable in character. In addition, the invention further discloses a preparation method of the cell strain. The human prostate cancer cell disclosed by the invention has the biology characters of clinical essential prostate, and can be applied to molecular mechanism researches on pathogenesis, invasion and metastasis of prostate, pharmacodynamics study and detection on anti-cancer medicines selected in vitro.

Provided are methods and kits for staining cervical cell sample by contacting the cervical cell sample with a Ficus elastics plant extract, staining the cervical cell sample with New Fuchsin, and staining the cervical cell sample with Light Green or Fast Green. Also provided are method of diagnosing a pre-malignant or a malignant cervical tumor in a subject, by staining the cervical cell sample and identifying at least one cervical cell having a red cytoplasm above a pre-determined threshold, wherein presence of the at least one cervical cell having the red cytoplasm above the pre-determined threshold is indicative of a non- or less-differentiated cell as compared to a normal cervical cell, thereby diagnosing the pre-malignant or a malignant cervical tumor in the subject.

The invention discloses 11 segments of human alimentary canal tumor blood vessel specific binding cyclic peptide series. The present invention utilizes a random phage cyclic 7 peptide library and an immunosuppressed mouse subrenal capsule human metastatic tumor model to successfully screen out a cyclic 7 that can specifically bind to blood vessels of human esophageal squamous cell carcinoma and human gastric poorly differentiated adenocarcinoma Peptides GX1-GX11. Plaque titration of transplanted tumor tissues, immunohistochemical staining of transplanted tumor tissues and human gastric cancer and esophageal cancer tissues, and competition inhibition experiments between GX1 synthetic peptides and GX1-presenting phages in vivo showed that the series of 7 peptides combined with blood vessels in human digestive tract tumor tissues specificity. The uniqueness of these protein sequences was confirmed after sequencing. These polypeptide sequences will have great potential value in the targeted therapy of tumor blood vessels and the development of specific molecular marker reagents for tumor blood vessels.

The invention discloses a monoclonal antibody resisting the ovarian cancer and application thereof. A hybridoma cell strain NM003-1 secreting the monoclonal antibody resisting the human ovarian cancer is preserved in China Center for Type Culture Collection on September 26, 2011 with the preservation number of CCTCC NO: C201174. The hybridoma cell strain NM003-1 secretes the monoclonal antibody NJ003-1 resisting the human ovarian cancer. Expression of a specific antigen of the monoclonal antibody NJ003-1 in ovarian cancer tissue is higher than that in ovarian benign disease tissue; the positive expression rate of the antigen in a poorly differentiated patient is higher than that in a well differentiated patient. The monoclonal antibody NJ003-1 can effectively inhibit clone formation of ovarian carcinoma cells SK-OV-3 in soft agar and can remarkably inhibit growth of human ovarian cancer transplantation tumors in a nude mouse. Obviously, the monoclonal antibody is expected to become medicine for treating the ovarian cancer or to be prepared into a diagnostic reagent for detecting the ovarian cancer.

The invention discloses an application of using CtBP2 as a marker in the preparation of diagnostic products for hepatocellular carcinoma and intrahepatic cholangiocarcinoma, and belongs to the technical field of biomedicine. The research results of the present invention show that most high-moderately differentiated HCCs are negative for CtBP2, and only a few poorly differentiated HCCs are positive; while in ICC, CtBP2 is diffusely strongly positive. Therefore, CtBP2 can be used as a marker to prepare related products for the identification and diagnosis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma, thereby providing a new method for the identification, diagnosis or drug efficacy evaluation of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. objective indicators.